ABSTRACT: Background: The tau PET ligand 2-((1E,3E)-4-(6-([
As a result of a lack of specific biomarkers, it is challenging to make a correct antemortem diagnosis of neurodegenerative disease. [1] [2] [3] [4] [5] [6] Because diagnoses of these diseases are confirmed at autopsy, the discrepancies between clinical diagnosis and pathologic diagnosis are inevitable. Inaccurate antemortem diagnosis of neurodegenerative diseases affects the quality of clinical studies for exploring potential biomarkers and assessing the therapeutic effect of promising drugs. 7 To improve the antemortem diagnostic accuracy of neurodegenerative diseases such as tauopathies and asynucleinopathies, it is useful to establish assay systems to visualize pathognomonic pathology for these diseases.
Alzheimer's disease (AD), the most common neurodegenerative disease of dementia, has 2 proteins as pathologic hallmarks: amyloid and tau. 8, 9 Amyloid positron emission tomography (PET) imaging using [ 11 C]Pittsburgh Compound B (PiB) has been sucsessfully used to detect cerebral amyloid deposition in individuals with AD. 10, 11 Recently, PET imaging of tau lesions has become available using several tau PET ligands, such as 2-((1E,3E)-4-(6-([ 
------------------------------------------------------------and [
18 F]THK arylquinoline series. [12] [13] [14] These tau ligands bind to b-pleated sheet secondary structures in tau filaments and detect tau pathology in AD as well as non-AD tauopathies. [15] [16] [17] [18] One such tau PET ligand, PBB3, has shown high-affinity binding to a wide range of tau pathologies-not only neurofibrillary tangles (NFTs) in AD but also tufted astrocytes in progressive supranuclear palsy (PSP), astrocytic plaques in corticobasal degeneration (CBD), and coiled bodies and threads in both diseases. 12 A recent study on the head-to-head comparison of [ 11 
C]PBB3 and [
18 F]AV-1451 has shown that PBB3 bound avidly to neuronal and glial tau lesions in PSP and CBD, whereas AV-1451 showed only vague binding. 19 This indicates the high sensitivity of [ 11 C]PBB3 for tau pathology; however, there is limited knowledge regarding the selectivity of [ 11 C]PBB3 for other amyloidogenic proteins such as a-synuclein. Thioflavin S, a fluorescence compound binding to b-pleated sheet-rich structures, is widely used to stain amyloid and tau aggregates 9, 20, 21 ; however, it also labels a-synuclein pathology exemplified by Lewy bodies and glial cytoplasmic inclusions (GCIs). 22 A recent study on [
18 F]AV-1451-PET scan has revealed significant retention in the posterior putamen in patients with MSA. 23 These findings pose the possibility that PBB3 also binds to a-synuclein pathology. Given that a-synucleinopathy is often misdiagnosed as tauopathy, 5, 6 it is important to clarify whether [ 11 C]PBB3 binds to a-synuclein pathology to avoid misinterpretation and incorrect diagnosis. To address this issue, the reactivity of PBB3 with asynuclein inclusions was assessed by in vitro fluorescence and autoradiographic labeling of brain sections from patients with Lewy body disease (LBD) and multiple system atrophy (MSA).
Subjects and Methods

Case Selection
All brain autopsies were performed after consent of the legal next of kin or an individual with power of attorney. Studies of autopsy samples were considered exempt from human subject research by the Mayo Clinic Institutional Review Board. The research using autopsied human samples was approved by the Ethics Committee of National Institute of Radiological Sciences, Japan. To confirm binding specificity of PBB3 to tau, we included a neuropathologically normal individual (n 5 1), AD (n 5 1), 8, 9 Pick's disease (n 5 1), 24 and PSP (n 5 1). 25 To clarify whether PBB3 binds to a-synuclein pathology, we examined asynucleinopathies that included LBD with no NFTs or amyloid b deposits (so called pure-form LBD, n 5 3) 26, 27 and MSA (n 5 5). 28 This selection of asynucleinopathies was based on the quantitative analysis of a-synuclein burden (see later) in 10 LBD and 120 MSA cases. LBD cases were chosen to include those with the least burden (LBD-1), median burden (LBD-2), or greatest burden (LBD-3) of a-synuclein. The MSA cases were chosen to include the least burden (MSA-1), burden at the 25th percentile (MSA-2), burden at the 75th percentile (MSA-3), and greatest burden (MSA-4) of a-synuclein (see later; Fig. 1 ). To assess a-synuclein pathology, including neuronal cytoplasmic inclusions (NCIs), we also included an MSA case with abundant NCIs in the hippocampus (MSA-5). Demographic and pathologic characteristics of 12 cases are summarized in Table 1 .
Neuropathologic Assessment
Formalin-fixed brains underwent systematic and standardized sampling with neuropathologic evaluation by a single experienced neuropathologist (D.W.D). Braak NFT stage and Thal amyloid phase were assigned by microscopic examinations of sections stained with thioflavin S according to published criteria. 29, 30 Immunohistochemistry for a-synuclein (NACP; Mayo Clinic [Jacksonville, Florida] antibody) 31 and phospho-tau (CP13, 1:1000; a gift from Dr. Peter Davies, Feinstein Institute for Medical Research, LIJ-North Shore Health System, New York) was conducted to establish neuropathological diagnosis as described previously. 32, 33 Prussian blue stain was used to evaluate iron deposits. 34 Deparaffinized slides were incubated with Prussian blue staining solution (equal volumes of 20% hydrochloric acid and 10% potassium ferrocyanide aqueous solution) for 20
Cases with Lewy body disease (LBD) and MSA are selected based on the quantitative analysis of a-synuclein burden. The graph shows %area of NACP-immunoreactive pixels to the total area of the annotated region (the amygdala in LBD and the striatopallidal fibers in MSA). Minimum, 25th percentile, median, 75th percentile, and maximum values are 0.1% (LBD-1), 0.8%, 1.2% (LBD-2), 1.6%, and 2.7% (LBD-3) in LBD cases (n 5 10) and 0.1% (MSA-1), 1.2% (MSA-2), 2.5%, 4.4% (MSA-3), and 7.3% (MSA-4) in MSA cases (n 5 120).
minutes at room temperature. Slides were counterstained with Nuclear Fast Red Kernechtrot 0.1% (Poly Scientific R&D Corp, Bay Shore, New York) and coverslipped.
To assess a-synuclein burden quantitatively, sections of the amygdala and basal ganglia from the LBD and MSA cases were scanned on the ScanScopeXT (Aperio Technologies, Vista, California) The amygdala in LBD cases and striatopallidal fibers in MSA cases were annotated using ImageScope-11.2 (Aperio Technologies) because these regions had the greatest density of Lewy bodies in LBD 35, 36 and GCIs in MSA 31 . Annotated regions were analyzed in Spectrum-11.2 using a custom-designed color deconvolution algorithm to detect only NACP-positive pathology. A burden of asynuclein pathology was expressed as a percent ratio of the area of immunoreactive pixels to the total area of the annotated region ( Supplementary Fig. 1 ).
PBB3 Fluorescence Labeling and Immunofluorescence Doublestaining
Following deparaffinization, antigen retrieval was performed by steaming slides in distilled water for 30 minutes. Then slides were incubated in 32.3 mM of PBB3 with 50% ethanol for 30 minutes at room temperature. Subsequently, the slides were immersed in 50% ethanol for several dips for decolorization and in deionized water for 5 minutes. The slides were coverslipped with Vectashield mounting media (Vector Laboratories, Burlingame, California). PBB3 fluorescence images were captured by BX50 fluorescent microscope (Olympus Co. Ltd., Tokyo, Japan) using U-MWBV2 blue-violet excitation fluorescence filter (Olympus Co. Ltd., excitation wavelength: 400-440 nm, emission wavelength: 475 nm). After capturing the images, the coverglass was removed. Sections were pretreated with 95% formic acid for 30 minutes, steamed in distilled water for 30 minutes, blocked with Protein Block plus Serum Free (Dako, Carpinteria, California) for 1 hour, and then incubated with anti-NACP (1:2000) and anti-CP13 (1:500) primary antibodies diluted in with Antibody Diluent with Background-Reducing Components (Dako) overnight at 4 8C. Sections were washed three times with 1xPBS (Sigma-Aldrich, St. Louis, Montana) at room temperature and then incubated with secondary antibodies Alexa Fluor 488 and Alexa Fluor 568 (1:500, Thermo Fisher Scientific Inc., Waltham, Massachusetts) and diluted with Antibody Diluent for 1.5 hours at room temperature in a dark chamber. Sections were washed three times with 1xPBS and mounted with Vectashield mounting media. Representative images were taken with the BX50 fluorescent microscope.
Thioflavin S Fluorescence and Immunofluorescence Doublestaining
Following deparaffinization, the slides were incubated in thioflavin S solution for 7 minutes at room temperature. Subsequently, the slides were immersed in 70% ethanol for several dips for decolorization and in deionized water for 1 minute. The slides were coverslipped with Vectashield mounting media (Vector Laboratories). Subsequent procedures were the same as PBB3 fluorescence labeling and immunofluorescence doublestaining.
Radiosynthesis
[ 11 C]PBB3 was radiosynthesized using its desmethyl precursor as described previously in detail. 12, 37 Specific activity of [ 
In Vitro Autoradiography
In vitro autoradiography was performed using 6-mmthick deparaffinized sections derived from LBD and MSA brains. For labeling with [ and phospho-tau (CP13, 1:500). PBB3 labels tau pathology; neurofibrillary tangles in Alzheimer's disease (AD; A), Pick body in Pick's disease (B), and coiled body in PSP (C), which are positive for CP13 but negative for NACP. PBB3 also labels a-synuclein pathology; brainstem type Lewy body (D) and Lewy neurites (E) in LBD, and glial cytoplasmic inclusion (F) and neuronal cytoplasmic inclusions (G) in MSA, which are positive for NACP but negative for CP13. Bar 5 20 mm. All images are the same magnification. [Color figure can be viewed at wileyonlinelibrary.com]
were subsequently dried by treating with warm air and exposed to an imaging plate (BAS-MS2025; Fuji Film, Tokyo, Japan). The imaging plate was scanned with BAS-5000 system (Fuji Film) to acquire autoradiograms. Excess concentration (100 mM) of PBB5 was added to the reaction to determine nonspecific radiotracer binding. All autoradiography procedures with [ 11 C]PBB3 were performed without exposure to fluorescence lights to circumvent photoisomerization of this compound. 37 
Results
Fluorescence Labeling With PBB3
To confirm binding of PBB3 to tau aggregates, we examined fluorescence labeling and immunofluorescence doublestaining with anti-NACP and anti-CP13 antibodies in tauopathy cases. As expected, PBB3 labeled a wide range of tau pathology, including NFTs and threads in AD, Pick bodies in Pick's disease, and coiled bodies and tufted astrocytes in PSP, which were positive for CP13 and negative for NACP ( Fig. 2A-C) . Next, we applied the same analysis to asynucleinopathies. In LBD, PBB3 labeled brain stemtype Lewy bodies in the substantia nigra (Fig. 2D) , basal nucleus of Meynert, and hypothalamus; cortical type Lewy bodies in the CA4 sector and entorhinal cortex; abundant dystrophic Lewy neurites in the CA2/CA3 sectors (Fig. 2E) ; and spheroids in the substantia nigra and basal nucleus of Meynert. These PBB3-positive lesions were also positive for NACP and negative for CP13 (Fig. 2D,E) . In MSA cases, PBB3 labeled abundant GCIs in the putamen, especially in striatopallidal fibers, globus pallidus (Fig. 2F) , hypothalamus, amygdala, and internal capsule of all MSA cases. Many NCIs in the pyramidal layer of CA1/subiculum (Fig. 2G ) and dentate gyrus of MSA-5 were labeled by PBB3. Immunofluorescence doublestaining confirmed that these GCIs and NCIs were positive for NACP and negative for CP13 (Fig. 2F,G) . In a neurologically normal control subject with no NFTs, amyloid b, or a-synuclein pathology, PBB3 did not label any significant pathology, although lipofuscin autofluorescence was present (Supplementary Fig.  2 ). To further support PBB3 binding to both tau and a-synuclein pathologies with fibrillar b-pleated sheet structures, thioflavin S staining was performed. As with PBB3, thioflavin S labeled tau pathology (NFTs, threads, Pick bodies, coiled bodies, and tufted astrocytes) as well as a-synuclein pathology (Lewy bodies, Lewy neurites, GCIs, and NCIs [ Supplementary Fig.  3] ). It is noteworthy that binding of both PBB3 (Supplementary Fig. 2 ) and thioflavin S to Lewy-related pathology, GCIs and NCIs disappeared after formic acid treatment, which disrupts b-pleated sheet structure.
21,38
Autoradiographic Labeling With [
C]PBB3
To assess binding of [ 11 C]PBB3 to a-synuclein pathology at a low concentration (10 nM), we performed autoradiography using sections of the amygdala and basal ganglia from the LBD and MSA cases. The total binding of [ 11 C]PBB3 was almost completely abolished after adding excessive nonradioactive PBB5, indicating the specificity of the signal. The 3 LBD cases showed no [ 11 C]PBB3 binding in the amygdala, basal forebrain, or basal ganglia, areas with significant a-synuclein immunoreactivity on the adjacent sections (Fig. 3A) . In contrast, MSA cases showed specific binding of [ (Fig.  3B ). MSA-3, which had severe a-synuclein pathology, showed weak [ 11 C]PBB3 radiosignals in striatopallidal fibers that had many GCIs (Fig. 3B) . MSA-4, the case with the greatest burden of a-synuclein, showed strong radioligand binding to the putamen, especially to the striatopallidal fibers that corresponded to an area with extremely high density of GCIs (Fig. 1) . Immunohistochemistry for phospho-tau confirmed the absence of tau pathology in this region. Taken together, the results of autoradiography in MSA most likely represent the binding of [
11 C]PBB3 to GCIs, not tau pathology. In all images, minor binding was seen in the anterior commissure and optic tract. This signal was considered to be a result of nonspecific binding to unknown molecular structures as reported in amyloid b-targeting tracers. 39, 40 To clarify whether [ 11 C]PBB3 also binds to NCIs, we examined autoradiography using a section of the hippocampus of MSA-5; however, it showed no [ 11 C]PBB3 binding in this region (data not shown). Although MSA-5 had abundant NCIs in the hippocampus, the density of NCIs was much lower than that of GCIs: < 0.1% in the CA1 sector (mainly NCIs) and 2.1% in the hippocampal alveus (mainly GCIs).
Assessment of Iron Deposits
The result of the recent study on [ 23 Therefore, to clarify whether autoradiographic binding of [ 11 C]PBB3 to the striatopallidal fibers was because of the presence of iron deposits, we performed Prussian blue staining in 3 LBD and 4 MSA cases. Variable degree of iron deposits was detected throughout the sections, especially in the globus pallidus and putamen in all cases (dense staining was marked with arrows in Supplementary Fig. 4 ). Although LBD-1 and LBD-3 showed abundant iron deposits within the striatopallidal fibers (Supplemental Fig. 4 , LBD-1 and LBD-3), no autoradiographic binding of [ 
Discussion
The present study had 2 major findings. First, tau PET ligand PBB3 at a high concentration (32.3 mM) can bind to not only tau, but also a-synuclein pathology, including Lewy bodies, Lewy neurites, spheroids, GCIs, and NCIs, because fluorescence labeling of these lesions with PBB3 was observed in all cases we examined. Second, autoradiographic evaluation of [ 11 C]PBB3 at a low concentration (10 nM) showed no binding to a-synuclein pathology in LBD cases, but MSA cases with a high burden of a-synuclein pathology (MSA-3 and MSA-4) had significant radioligand binding to the striatopallidal fibers, which corresponded to abundant GCIs in this region.
Although various types of a-synuclein pathology were captured by PBB3 fluorescence labeling, it should be noted that structures labeled by PBB3 fluorescence were not necessarily detected by autoradiography. The high sensitivity of fluorescence labeling is consistent with literature on another tau ligand [ 
preferentially bound to paired helical filaments (PHFs), rather than straight filaments. 41, 42 Marquie and colleagues reported, however, that the AV-1451 fluorescent analogue also labeled non-PHF-tau lesions, amyloid plaque cores, and amyloid-laden vessels at high concentration. 41 In the present study, the concentration of PBB3 for fluorescence labeling (32.3 mM) experiment is much higher than that for autoradiography (10 nM). The higher concentration may attribute to greater sensitivity and less specificity of fluorescence labeling, as the compound could cross-react with lowaffinity, high-capacity binding sites in non-tau fibers.
The current autoradiographic evaluations indicated distinct detectabilities of a-synuclein inclusions in LBD and MSA by [ 11 C]PBB3. We did not find any positive radiosignals in LBD, even in a case with the most severe a-synuclein deposition (LBD-3) . Given the relatively low density of a-synuclein pathology within the amygdala (compared to the density of those within the striatopallidal fibers of MSA; see Fig. 1 [45] [46] [47] Although we do not have the direct evidence that PBB3 binds MAOs (ie, MAO-A and MAO-B) yet, the autoradiographic signals in the striatopallidal fibers are unlikely due to the off-target binding in MAOs because both MAOs are found in neurons and astroglia, but not in oligodendrocytes. 48 To determine the binding of [
11 C]PBB3 to MAOs, in vivo PET studies with MAOs inhibitors are needed.
As with tauopathy, a-synucleinopathy is one of the major categories of neurodegenerative disease. The fact that clinical presentations of a-synucleinopathies such as dementia and parkinsonism often mimic the clinical phenotype of tauopathies makes accurate antemortem diagnosis difficult. 5, 6 Imaging modalities to differentiate tauopathy and a-synucleinopathy will solve this clinical challenge. Our present study raises the possibility that derivative compounds of [ 11 C]PBB3 might be potential candidates as asynuclein PET ligands. The fact that PBB3 potentially binds to a-synuclein pathology can be explained by the fact that PBB3 binds to b-pleated sheet structures and a-synuclein filaments have a b-pleated sheet conformation that is similar to the structure described for amyloid fibrils. 49, 50 53 it would be possible to detect Lewy pathology if the a-synuclein PET ligand has high enough binding affinity, at least 10 to 50 times higher than that of PBB3. The threshold of signal detection can be confirmed by direct comparison between in vivo PET imaging and postmortem pathology in the same subjects. As Murray and colleagues 54 clarified the cut-off standardized uptake value of [ 11 C]PiB-PET, which was approximately equivalent to Thal amyloid phase of 1-2, this type of study will determine whether the asynuclein PET ligand can detect the a-synuclein pathology even in the early stages of Parkinson's disease.
A major limitation of this study is the lack of in vivo [ 11 C]PBB3-PET imaging in patients with asynucleinopathy, which prevents direct comparisons between in vivo and postmortem neuropathology in the same subjects. Because the results of in vitro autoradiography are not always directly reflective of the in vivo PET scans, it is imperative to conduct an in vivo [ 11 C]PBB3-PET imaging study on patients with asynucleinopathy to validate the results of present study. Another limitation is that we used phosphorylationdependent tau antibody (CP13) to assess tau pathology in MSA cases. Because the presence of unphosphorylated tau in GCI was reported, 55 we might fail to evaluate the presence of this type of tau in GCI. We assume, however, that the contribution of the unphosphorylated tau might be minimal because these tau proteins are not the principal constituents of the fibrillary structures of GCIs. 56 A notable strength of our study is that we selected cases based on quantitative analysis of asynuclein burden. We performed autoradiography using cases with a wide range of a-synuclein burden, including an MSA case with the highest a-synuclein burden in our brain bank. Although recent studies have shown that [ 18 F]AV-1451 do not seem to bind a-synuclein pathology, 41, 42 the burden of a-synuclein in cases studied was not described. It is important to compare a wide range of a-synuclein burden in each asynucleinopathy to assess binding properties of PBB3 and its derivatives. Another advantage of this study is that we examined pure LBD cases rather than LBD cases with varying amounts of coexisting Alzheimertype pathology. If these LBD cases were included in this study, it would be hard to interpret whether observed binding of PBB3 was to a-synuclein, tau, or Ab.
In conclusion, the present results suggest that asynuclein pathology in LBD would not be detectable by [ 11 C]PBB3-PET, whereas a subset of severe MSA cases with high density of a-synuclein pathology might be positive. Further studies including direct comparison between in vivo PET images and postmortem neuropathology in the same subjects are necessary to demonstrate the usefulness of [
11 C]PBB3-PET to differentiate tauopathies from a-synucleinopathies.
